Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Inovio Pharmaceuticals Inc

INO
Current price
0.41 USD +0.022 USD (+5.77%)
Last closed 0.4 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 108 648 424 USD
Yield for 12 month -78.11 %
Week
Month
Year
INO
21.11.2021 - 28.11.2021

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania. Address: 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

Analytics

WallStreet Target Price

1.2 USD

P/E ratio

Dividend Yield

1.52 %

Current Year

+10 262 268 USD

Last Year

+1 774 758 USD

Current Quarter

+388 446 USD

Last Quarter

+225 971 USD

Current Year

+10 262 268 USD

Last Year

+1 774 758 USD

Current Quarter

+388 446 USD

Last Quarter

+225 971 USD

Key Figures INO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -158 782 064 USD
Operating Margin TTM -6446.11 %
PE Ratio
Return On Assets TTM -34.61 %
PEG Ratio
Return On Equity TTM -81.3 %
Wall Street Target Price 1.2 USD
Revenue TTM 854 025 USD
Book Value 0.51 USD
Revenue Per Share TTM 0.003 USD
Dividend Share
Quarterly Revenue Growth YOY -95.8 %
Dividend Yield 1.52 %
Gross Profit TTM -177 388 235 USD
Earnings Share -0.63 USD
Diluted Eps TTM -0.63 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics INO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History INO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 1.52 %
Last Split Factor 1:4
Payout Ratio
Last Split Date 06.06.2014
Dividend Date

Stock Valuation INO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 19.096
Price Sales TTM 127.2193
Enterprise Value EBITDA 0.1848
Price Book MRQ 0.7842

Financials INO

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators INO

For 52 weeks

0.32 USD 1.99 USD
50 Day MA 0.41 USD
Shares Short Prior Month 24 939 855
200 Day MA 0.62 USD
Short Ratio 9.3
Shares Short 25 947 330
Short Percent 10.82 %